Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

A number of other equities analysts have also weighed in on ADAP. TheStreet lowered Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, July 16th. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Wednesday, July 18th. BidaskClub lowered Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 21st. Guggenheim initiated coverage on Adaptimmune Therapeutics in a research note on Monday, September 17th. They set a “buy” rating on the stock. Finally, Raymond James lowered their price objective on Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Adaptimmune Therapeutics currently has an average rating of “Buy” and a consensus price target of $15.44.

NASDAQ ADAP opened at $6.18 on Thursday. The firm has a market cap of $627.87 million, a price-to-earnings ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a fifty-two week low of $5.73 and a fifty-two week high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.09. The company had revenue of $40.79 million for the quarter, compared to analyst estimates of $29.41 million. Adaptimmune Therapeutics had a negative return on equity of 41.63% and a negative net margin of 139.57%. Equities analysts forecast that Adaptimmune Therapeutics will post -0.98 EPS for the current fiscal year.

In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total value of $256,250.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $5,010,000.00. The disclosure for this purchase can be found here. Corporate insiders own 26.47% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA acquired a new position in shares of Adaptimmune Therapeutics in the 2nd quarter valued at $122,000. BB&T Securities LLC acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth about $128,000. Jane Street Group LLC acquired a new position in Adaptimmune Therapeutics during the 1st quarter worth about $168,000. Trexquant Investment LP acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth about $178,000. Finally, Trellus Management Company LLC acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth about $195,000. 58.99% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Read More: What is Cost of Debt?

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.